Published in Health Risk Factor Week, April 11th, 2006
Researchers in Italy conducted a study to "evaluate the safety of treatment interruption (TI) guided by CD4+ count in HIV-infected patients followed-up prospectively."
A. Boschi and colleagues at AUSL Rimini explained, "Patients on HAART with a CD4+ cell count >500 cells/mm3 discontinued therapy with instructions to start therapy again before their CD4+ count dropped below 200 cells/mm3. We report data on 112 HIV-infected patients."
"The median follow-up after starting the first TI was 34.7 months...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Health Risk Factor Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.